Pronova opens up Japanese market


Lysaker/Osaka - Pronova Biopharma SA is set on entering the Japanese market with its TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia. Pronova's partner Takeda Pharmaceutical Company Limited submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare. Their application is the fruit of a long-standing relationship. In 2005, Takeda and Pronova entered into a License and Supply Agreement in which Takeda was granted the exclusive development and marketing rights to this product in Japan. TAK-085, discovered by Pronova, is the omega 3-derived prescription drug containing highly concentrated and purified EPA-E (eicosapentaenoic acid ethyl ester) and DHA-E (docosahexaenoic acid). The submission is based on the results of the phase 3 clinical trial to evaluate the efficacy and safety of TAK-085 in comparison with an active comparator EPA product already marketed in Japan. The trial demonstrated that 4g per day of TAK-085 was statistically superior to 1.8g per day of the EPA. The drug is already on the market in 56 countries including the U.S. and most European countries.



Oslo – Photocure ASA, one of the Norwegian biotech companies established around the Radium Hospital in Oslo and listed on the Oslo Stock Exchange since 2000, has proposed a demerger of its cancer-focused drug delivery subsidary...

Norway, BioFundingNorway


Tromsø/Oslo – Two Norwegian companies have raised fresh money to further develop their therapeutic programmes. Tromsø-based Lytix Biopharma AS recently completed a private placement of EUR6.2m (NOK 50m). The money will be used to...

Norway, BioFundingNorway


Oslo – Norwegian company Aqua Bio Technology ASA kicked off the new year with an initial public offering on the new Oslo Axess Exchange. The first day of public trading was January 10. Compared to a listing on the Oslo Børs,...

Norway, BeNeLuxNorway


Brussels/Oslo – Belgian antibody fragment specialist Ablynx has raised a75 million in its IPO through the sale of 10.7 million shares at a7 on the Brussels Euronext stock market Eurolist. The company received a total valuation...



Lysaker – Norwegian company Pronova BioPharma ASA, specialists in omega-3-derived products, has raised EUR73.7 million (NOK575 million) through the sale of 25 million shares at EUR2.9 (NOK23) per share in an IPO on the Oslo Stock...



Oslo – The Research Council, in cooperation with Innovation Norway and the Industrial Development Corporation of Norway (SIVA), has appointed an international group of experts to map out the potential of the bioprospecting field...



Oslo – The Norwegian biobank project HUNT, which is attached to the Norwegian University of Science and Technology and based in the region of Nord-Trondelag has established a commercial company to facilitate relationships with...



Oslo – Norwegian antibody therapeutics company Affitech AS has signed a research and licensing agreement with Swiss pharma company Roche to produce human monoclonal antibodies against an unspecified oncology target. Affitech will...



Oslo – The Norwegian government has announced funding for functional genomics research of around €113 million (NOK 420million) over the coming five years. The money is being granted for the continuation of the funding...



Oslo – Algeta ASA, a Norwegian cancer therapeutics company, has completed its listing on the Oslo Stock Exchange. The shares began trading on 27 March. The initial public offering raised gross proceeds of approximately NOK 250...

Displaying results 41 to 50 out of 92

< Previous 41-50 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%


  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015

Current issue

All issues